Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 10;4(3):770-774.
doi: 10.1002/jha2.749. eCollection 2023 Aug.

Vidjil add-on for MRD quantification of samples processed using the EuroClonality-NGS protocol

Guilherme Navarro Nilo Giusti  1   2 , Antonio Vítor Ribeiro  3 , Patrícia Yoshioka Jotta  1 , Florian Thonier  4 , José Andrés Yunes  1   5 , João Meidanis  6
Affiliations

Vidjil add-on for MRD quantification of samples processed using the EuroClonality-NGS protocol

Guilherme Navarro Nilo Giusti et al. EJHaem. .

Abstract

Assessment of minimal residual disease in acute lymphoblastic leukemia by immune repertoire NGS requires spiking CDR3 sequences at known quantities into the patient's sample. Recently, the EuroClonality-NGS group released one of the most comprehensive protocols for this purpose. ARResT/Interrogate is a closed-source software for processing these NGS libraries, developed by this same group. Vidjil, an open-source alternative, currently cannot handle libraries prepared using this protocol. Here, we present a Vidjil add-on to solve this issue. EuroClonality-NGS prepared samples analyzed with Vidjil and ARResT/Interrogate were highly concordant (r = 0.998) and presented low error (root-mean-square error, RMSE = 0.112).

Keywords: T‐cell receptor; Vidjil; immune repertoire; immunoglobulin genes; leukemia; minimal residual disease.

PubMed Disclaimer

Conflict of interest statement

The institution Centro Infantil Boldrini is a part of the VidjilNet Consortium. Florian Thonier is a developer in the Vidjil team.

Figures

FIGURE 1
FIGURE 1
EuroClonality versus ARResT/Interrogate: IG/TR marker quantification and cIT‐QC identification. Analysis of bone marrow NGS files from the original cIT‐QC publication [6]. Samples S1‐S32 correspond to diagnostic B/T‐ALL, while S33‐S48 to aplastic posttreatment. (A and B) Linear regression of the log10 cell frequency for IG/TR clonotypes calculated by ARResT/Interrogate and Vidjil. Pearson's correlation coefficient represented by r, and root‐mean‐square error by RMSE. Vidjil analysis without (A) and with manual clonotype clustering (B). (C, D, and E) ARResT/Interrogate and Vidjil comparison per sample of total cIT‐QC read count (C), total IG/TR rearrangement read count (D), and total cIT‐QC read frequency (total cIT‐QC reads/total V(D)J reads) (E). Green and black arrows indicate samples where a cIT‐QC sequence was missing in both software tools and only in Vidjil, respectively.
See this image and copyright information in PMC

References

    1. van Dongen JJM, Seriu T, Panzer‐Grümayer ER, Biondi A, Pongers‐Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731–8. - PubMed
    1. van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM. Detection of minimal residual diseasein hematologic malignancies by real‐time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013–34. - PubMed
    1. Tran TH, Hunger SP. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. Semin Cancer Biol. 2020;84:144–52. - PubMed
    1. Faham M, Zheng J, Moorhead M, Carlton VEH, Stow P, Coustan‐Smith E, et al. Deep‐sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173–80. - PMC - PubMed
    1. Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing‐based post‐remission MRD surveillance predicts clinical relapse in B‐ALL. J Hematol Oncol. 2018;11(1):105. - PMC - PubMed